CD4 and neoplasm: Since our group and others have shown that Her2 can down-modulate MHC class I expression [38-40], tumor vaccine strategies such as pDNA administration that are not solely dependent on CTLs but induce an integrated immune response involving also antibodies and CD4+ T-cells should be advantageous.